Peloton Therapeutics, Inc., a drug discovery and development company focused on advancing first-in-class, small molecule cancer therapies, announced today the exercise of an optional tranche of its previously-announced Series D financing round. With the exercise of this optional tranche, investors added $22.2 million to the earlier Series D close of $52.4 million, bringing the full amount raised in the Series D financing round to $74.6 million.

“This financing represents a strong vote of confidence in our science and the value of our programs, including the potential of our HIF-2α antagonists to impact the treatment of renal and other cancers,” said John A. Josey, Ph.D., Peloton’s Chief Executive Officer. “We are pleased with the continued support from our investors.”